Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 460

1.

Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD.

Nat Immunol. 2019 Oct 11. doi: 10.1038/s41590-019-0531-x. [Epub ahead of print]

PMID:
31605100
2.

'Stealth' corporate innovation: an emerging threat for therapeutic drug development.

Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD.

Nat Immunol. 2019 Sep 27. doi: 10.1038/s41590-019-0503-1. [Epub ahead of print] No abstract available. Erratum in: Nat Immunol. 2019 Oct 11;:.

PMID:
31562490
3.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ.

Alzheimers Dement. 2019 Sep 5. pii: S1552-5260(19)35118-0. doi: 10.1016/j.jalz.2019.06.4951. [Epub ahead of print]

4.

Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Chamberlain JL, Huda S, Whittam DH, Matiello M, Morgan BP, Jacob A.

J Neurol. 2019 Sep 3. doi: 10.1007/s00415-019-09498-4. [Epub ahead of print] Review.

PMID:
31482201
5.

Compendium of current complement therapeutics.

Zelek WM, Xie L, Morgan BP, Harris CL.

Mol Immunol. 2019 Oct;114:341-352. doi: 10.1016/j.molimm.2019.07.030. Epub 2019 Aug 22. Review.

6.

Complement factor C5 inhibition reduces type 2 responses without affecting group 2 innate lymphoid cells in a house dust mite induced murine asthma model.

Yang J, Ramirez Moral I, van 't Veer C, de Vos AF, de Beer R, Roelofs JJTH, Morgan BP, van der Poll T.

Respir Res. 2019 Jul 24;20(1):165. doi: 10.1186/s12931-019-1136-5.

7.

Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease.

Baker E, Sims R, Leonenko G, Frizzati A, Harwood JC, Grozeva D; GERAD/PERADES; CHARGE; ADGC; EADI; IGAP consortia, Morgan K, Passmore P, Holmes C, Powell J, Brayne C, Gill M, Mead S, Bossù P, Spalletta G, Goate AM, Cruchaga C, Maier W, Heun R, Jessen F, Peters O, Dichgans M, FröLich L, Ramirez A, Jones L, Hardy J, Ivanov D, Hill M, Holmans P, Allen ND, Morgan BP, Seshadri S, Schellenberg GD, Amouyel P, Williams J, Escott-Price V.

PLoS One. 2019 Jul 8;14(7):e0218111. doi: 10.1371/journal.pone.0218111. eCollection 2019.

8.

Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species.

Zelek WM, Taylor PR, Morgan BP.

Immunology. 2019 Aug;157(4):283-295. doi: 10.1111/imm.13083. Epub 2019 Jun 17.

9.

Inflammatory biomarkers in Alzheimer's disease plasma.

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

10.

C5b9 Deposition in Glomerular Capillaries Is Associated With Poor Kidney Allograft Survival in Antibody-Mediated Rejection.

Goutaudier V, Perrochia H, Mucha S, Bonnet M, Delmas S, Garo F, Garrigue V, Lepreux S, Pernin V, Serre JE, Szwarc I, Merville P, Ramounau-Pigot A, René C, Visentin J, Morgan BP, Frémeaux-Bacchi V, Mourad G, Couzi L, Le Quintrec M.

Front Immunol. 2019 Mar 8;10:235. doi: 10.3389/fimmu.2019.00235. eCollection 2019.

11.

Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.

Carpanini SM, Torvell M, Morgan BP.

Front Immunol. 2019 Mar 4;10:362. doi: 10.3389/fimmu.2019.00362. eCollection 2019. Review.

12.

CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers.

Menny A, Serna M, Boyd CM, Gardner S, Joseph AP, Morgan BP, Topf M, Brooks NJ, Bubeck D.

Nat Commun. 2018 Dec 14;9(1):5316. doi: 10.1038/s41467-018-07653-5.

13.

Molecular pathogenesis of human CD59 deficiency.

Karbian N, Eshed-Eisenbach Y, Tabib A, Hoizman H, Morgan BP, Schueler-Furman O, Peles E, Mevorach D.

Neurol Genet. 2018 Oct 26;4(6):e280. doi: 10.1212/NXG.0000000000000280. eCollection 2018 Dec.

14.

Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers.

Zelek WM, Harris CL, Morgan BP.

Immunobiology. 2018 Dec;223(12):744-749. doi: 10.1016/j.imbio.2018.07.016. Epub 2018 Jul 20.

PMID:
30033110
15.

Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis.

Zelek WM, Stott M, Walters D, Harris CL, Morgan BP.

Immunology. 2018 Nov;155(3):396-403. doi: 10.1111/imm.12982. Epub 2018 Jul 30.

16.

CD93 regulates central nervous system inflammation in two mouse models of autoimmune encephalomyelitis.

Griffiths MR, Botto M, Morgan BP, Neal JW, Gasque P.

Immunology. 2018 Nov;155(3):346-355. doi: 10.1111/imm.12974. Epub 2018 Jul 11.

17.

Complement system biomarkers in epilepsy.

Kopczynska M, Zelek WM, Vespa S, Touchard S, Wardle M, Loveless S, Thomas RH, Hamandi K, Morgan BP.

Seizure. 2018 Aug;60:1-7. doi: 10.1016/j.seizure.2018.05.016. Epub 2018 May 24.

18.

Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis.

Michailidou I, Jongejan A, Vreijling JP, Georgakopoulou T, de Wissel MB, Wolterman RA, Ruizendaal P, Klar-Mohamad N, Grootemaat AE, Picavet DI, Kumar V, van Kooten C, Woodruff TM, Morgan BP, van der Wel NN, Ramaglia V, Fluiter K, Baas F.

Acta Neuropathol Commun. 2018 May 3;6(1):36. doi: 10.1186/s40478-018-0536-y.

19.

Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator.

Collibee SE, Bergnes G, Muci A, Browne WF 4th, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik FI, Morgans DJ Jr, Morgan BP.

ACS Med Chem Lett. 2018 Feb 13;9(4):354-358. doi: 10.1021/acsmedchemlett.7b00546. eCollection 2018 Apr 12.

20.

Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.

Mihai S, Hirose M, Wang Y, Thurman JM, Holers VM, Morgan BP, Köhl J, Zillikens D, Ludwig RJ, Nimmerjahn F.

Front Immunol. 2018 Mar 16;9:535. doi: 10.3389/fimmu.2018.00535. eCollection 2018.

21.

Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.

Zelek WM, Watkins LM, Howell OW, Evans R, Loveless S, Robertson NP, Beenes M, Willems L, Brandwijk R, Morgan BP.

Mult Scler. 2019 Apr;25(4):523-531. doi: 10.1177/1352458518758927. Epub 2018 Feb 9.

PMID:
29421990
22.

Introduction to complement in health and disease: novel aspects and insights.

Morgan BP, Kavanagh D.

Semin Immunopathol. 2018 Jan;40(1):1-2. doi: 10.1007/s00281-017-0664-7. Epub 2018 Jan 8. No abstract available.

PMID:
29313086
23.

Complement system biomarkers in first episode psychosis.

Kopczynska M, Zelek W, Touchard S, Gaughran F, Di Forti M, Mondelli V, Murray R, O'Donovan MC, Morgan BP.

Schizophr Res. 2019 Feb;204:16-22. doi: 10.1016/j.schres.2017.12.012. Epub 2017 Dec 24.

24.

Absence of CD59 in Guinea Pigs: Analysis of the Cavia porcellus Genome Suggests the Evolution of a CD59 Pseudogene.

Boshra H, Zelek WM, Hughes TR, Rodriguez de Cordoba S, Morgan BP.

J Immunol. 2018 Jan 1;200(1):327-335. doi: 10.4049/jimmunol.1701238. Epub 2017 Nov 22.

25.

Complement in the pathogenesis of Alzheimer's disease.

Morgan BP.

Semin Immunopathol. 2018 Jan;40(1):113-124. doi: 10.1007/s00281-017-0662-9. Epub 2017 Nov 13. Review. Erratum in: Semin Immunopathol. 2018 Sep 21;:.

26.

Effects of freezer storage time on levels of complement biomarkers.

Morgan AR, O'Hagan C, Touchard S, Lovestone S, Morgan BP.

BMC Res Notes. 2017 Nov 6;10(1):559. doi: 10.1186/s13104-017-2885-1.

27.

Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis.

Loveless S, Neal JW, Howell OW, Harding KE, Sarkies P, Evans R, Bevan RJ, Hakobyan S, Harris CL, Robertson NP, Morgan BP.

Brain Pathol. 2018 Jul;28(4):507-520. doi: 10.1111/bpa.12546. Epub 2017 Jul 30.

PMID:
28707765
28.

Molecular cell biology of complement membrane attack.

Morgan BP, Boyd C, Bubeck D.

Semin Cell Dev Biol. 2017 Dec;72:124-132. doi: 10.1016/j.semcdb.2017.06.009. Epub 2017 Jun 21. Review.

29.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Morgan BP.

Clin Immunol. 2017 Aug;181:24-28. doi: 10.1016/j.clim.2017.05.016. Epub 2017 May 31.

30.

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.

Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, Lu Q, Partridge JR, Patskovska L, Patskovsky Y, Almo SC, Jacobson MP, Hua L, Xu Q, Gwaltney SL 2nd, Yee C, Harris J, Morgan BP, James J, Xu D, Hutchaleelaha A, Paulvannan K, Oksenberg D, Li Z.

ACS Med Chem Lett. 2017 Jan 23;8(3):321-326. doi: 10.1021/acsmedchemlett.6b00491. eCollection 2017 Mar 9.

31.

Microbial Neuraminidase Induces a Moderate and Transient Myelin Vacuolation Independent of Complement System Activation.

Granados-Durán P, López-Ávalos MD, Cifuentes M, Pérez-Martín M, Fernández-Arjona MD, Hughes TR, Johnson K, Morgan BP, Fernández-Llebrez P, Grondona JM.

Front Neurol. 2017 Mar 7;8:78. doi: 10.3389/fneur.2017.00078. eCollection 2017.

32.

High Levels of Soluble C5b-9 Complex in Dialysis Fluid May Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients.

Mizuno M, Suzuki Y, Higashide K, Sei Y, Iguchi D, Sakata F, Horie M, Maruyama S, Matsuo S, Morgan BP, Ito Y.

PLoS One. 2017 Jan 3;12(1):e0169111. doi: 10.1371/journal.pone.0169111. eCollection 2017.

33.

The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer's Disease.

Morgan AR, Touchard S, O'Hagan C, Sims R, Majounie E, Escott-Price V, Jones L, Williams J, Morgan BP.

J Alzheimers Dis. 2017;56(1):25-36. doi: 10.3233/JAD-160889.

PMID:
27911318
34.

Highly selective inhibition of myosin motors provides the basis of potential therapeutic application.

Sirigu S, Hartman JJ, Planelles-Herrero VJ, Ropars V, Clancy S, Wang X, Chuang G, Qian X, Lu PP, Barrett E, Rudolph K, Royer C, Morgan BP, Stura EA, Malik FI, Houdusse AM.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7448-E7455. Epub 2016 Nov 4.

35.

Terminal complexes of the complement system: new structural insights and their relevance to function.

Morgan BP, Walters D, Serna M, Bubeck D.

Immunol Rev. 2016 Nov;274(1):141-151. doi: 10.1111/imr.12461. Review.

36.

Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.

Hakobyan S, Luppe S, Evans DR, Harding K, Loveless S, Robertson NP, Morgan BP.

Mult Scler. 2017 Jun;23(7):946-955. doi: 10.1177/1352458516669002. Epub 2016 Sep 9.

PMID:
27613120
37.

Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease.

Hakobyan S, Harding K, Aiyaz M, Hye A, Dobson R, Baird A, Liu B, Harris CL, Lovestone S, Morgan BP.

J Alzheimers Dis. 2016 Sep 6;54(2):707-16. doi: 10.3233/JAD-160420.

PMID:
27567854
38.

Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex.

Heurich M, Preston RJ, O'Donnell VB, Morgan BP, Collins PW.

Thromb Res. 2016 Sep;145:84-92. doi: 10.1016/j.thromres.2016.07.017. Epub 2016 Aug 2.

PMID:
27513882
39.

Complement is activated in progressive multiple sclerosis cortical grey matter lesions.

Watkins LM, Neal JW, Loveless S, Michailidou I, Ramaglia V, Rees MI, Reynolds R, Robertson NP, Morgan BP, Howell OW.

J Neuroinflammation. 2016 Jun 22;13(1):161. doi: 10.1186/s12974-016-0611-x.

40.

Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.

Towner LD, Wheat RA, Hughes TR, Morgan BP.

J Biol Chem. 2016 Jul 15;291(29):14927-38. doi: 10.1074/jbc.M115.708446. Epub 2016 May 19.

41.

Complement system activation contributes to the ependymal damage induced by microbial neuraminidase.

Granados-Durán P, López-Ávalos MD, Hughes TR, Johnson K, Morgan BP, Tamburini PP, Fernández-Llebrez P, Grondona JM.

J Neuroinflammation. 2016 May 21;13(1):115. doi: 10.1186/s12974-016-0576-9.

42.

Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma.

Williams PA, Tribble JR, Pepper KW, Cross SD, Morgan BP, Morgan JE, John SW, Howell GR.

Mol Neurodegener. 2016 Apr 6;11:26. doi: 10.1186/s13024-016-0091-6.

43.

Complement and Humoral Adaptive Immunity in the Human Choroid Plexus: Roles for Stromal Concretions, Basement Membranes, and Epithelium.

Moore GR, Laule C, Leung E, Pavlova V, Morgan BP, Esiri MM.

J Neuropathol Exp Neurol. 2016 May;75(5):415-28. doi: 10.1093/jnen/nlw017. Epub 2016 Mar 19.

44.

Editorial.

Morgan BP, Lachmann PJ Sir.

Immunobiology. 2016 Jun;221(6):699-700. doi: 10.1016/j.imbio.2016.02.005. Epub 2016 Feb 20. No abstract available.

PMID:
26979646
45.

Structural basis of complement membrane attack complex formation.

Serna M, Giles JL, Morgan BP, Bubeck D.

Nat Commun. 2016 Feb 4;7:10587. doi: 10.1038/ncomms10587.

46.

Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome.

Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z.

Mol Immunol. 2016 Mar;71:10-22. doi: 10.1016/j.molimm.2016.01.003. Epub 2016 Jan 27.

PMID:
26826462
47.

Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.

Bahia El Idrissi N, Hakobyan S, Ramaglia V, Geluk A, Morgan BP, Das PK, Baas F.

Clin Exp Immunol. 2016 Jun;184(3):338-46. doi: 10.1111/cei.12767. Epub 2016 Mar 31.

48.

Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice.

Bloom AC, Collins FL, Van't Hof RJ, Ryan ES, Jones E, Hughes TR, Morgan BP, Erlandsson M, Bokarewa M, Aeschlimann D, Evans BAJ, Williams AS.

Bone. 2016 Mar;84:253-261. doi: 10.1016/j.bone.2015.12.014. Epub 2015 Dec 22.

49.

An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice.

Ruseva MM, Ramaglia V, Morgan BP, Harris CL.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14319-24. doi: 10.1073/pnas.1513698112. Epub 2015 Nov 2.

50.

Complementing the inflammasome.

Triantafilou M, Hughes TR, Morgan BP, Triantafilou K.

Immunology. 2016 Feb;147(2):152-64. doi: 10.1111/imm.12556. Review.

Supplemental Content

Loading ...
Support Center